AxoGen (AXGN) Projected to Release Earnings on Wednesday

AxoGen (NASDAQ:AXGN) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $0.1340 per share and revenue of $73.18 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. The firm had revenue of $69.73 million for the quarter, compared to the consensus estimate of $67.10 million. On average, analysts expect AxoGen to post ($0.44) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.

AxoGen Stock Performance

Shares of NASDAQ AXGN opened at $36.17 on Wednesday. The company has a market capitalization of $1.94 billion, a PE ratio of -53.19 and a beta of 1.17. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. The company’s fifty day moving average price is $43.95 and its 200 day moving average price is $42.09. AxoGen has a 1 year low of $16.78 and a 1 year high of $52.91.

Analyst Ratings Changes

A number of research analysts have weighed in on AXGN shares. Morgan Stanley cut shares of AxoGen to a “hold” rating in a report on Tuesday, September 29th. Bank of America began coverage on shares of AxoGen in a research note on Monday, October 12th. They set a “buy” rating and a $52.00 target price on the stock. Jefferies Financial Group reissued a “buy” rating and set a $55.00 target price on shares of AxoGen in a research note on Wednesday, July 29th. Truist Financial dropped their target price on AxoGen from $60.00 to $53.00 and set a “buy” rating on the stock in a research report on Thursday, October 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AxoGen presently has an average rating of “Moderate Buy” and an average target price of $51.73.

Insiders Place Their Bets

In related news, Director Kathy Weiler sold 14,150 shares of AxoGen stock in a transaction on Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph A. Tyndall sold 3,500 shares of AxoGen stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total transaction of $173,950.00. Following the completion of the sale, the director directly owned 10,650 shares in the company, valued at $529,305. This represents a 24.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 98,503 shares of company stock valued at $4,656,947. Corporate insiders own 2.44% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.